Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Helix Acquisition Corp. II Class A Ordinary Shares (HLXB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: HLXB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -4.11% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 250.37M USD | Price to earnings Ratio 40.96 | 1Y Target Price - |
Price to earnings Ratio 40.96 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.14 - 11.59 | Updated Date 06/29/2025 |
52 Weeks Range 10.14 - 11.59 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -0.55% | Return on Equity (TTM) - |
Valuation
Trailing PE 40.96 | Forward PE - | Enterprise Value 249407715 | Price to Sales(TTM) - |
Enterprise Value 249407715 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 18909000 | Shares Floating 11706071 |
Shares Outstanding 18909000 | Shares Floating 11706071 | ||
Percent Insiders 5.82 | Percent Institutions 87.19 |
Upturn AI SWOT
Helix Acquisition Corp. II Class A Ordinary Shares
Company Overview
History and Background
Helix Acquisition Corp. II was a special purpose acquisition company (SPAC) formed in 2021. Its purpose was to identify and merge with a private company, thereby taking it public. The company focused on targets in the biotechnology sector.
Core Business Areas
- SPAC Formation: A blank check company with no operating history. Its primary activity was seeking a business combination.
Leadership and Structure
Helix Acquisition Corp. II was led by a management team experienced in the biotechnology and investment sectors. The organizational structure was typical for a SPAC, designed to facilitate a merger or acquisition.
Top Products and Market Share
Key Offerings
- Initial Public Offering: Raised capital through an IPO to fund a potential acquisition. No inherent products or services until a merger was completed. Competitors are other SPACs seeking acquisitions in the biotech space. No relevant market share data applies directly.
Market Dynamics
Industry Overview
The SPAC market was highly active in 2020-2021 but subsequently cooled down. Biotech SPACs aimed to capitalize on the high-growth potential of the sector but faced increased regulatory scrutiny and market volatility.
Positioning
Helix Acquisition Corp. II positioned itself as a vehicle for biotech companies to access public markets quickly. Its competitive advantage hinged on its management team's expertise and network within the biotech industry.
Total Addressable Market (TAM)
The TAM for biotech companies seeking public listings is substantial, potentially billions of dollars annually. Helix's positioning depended on attracting one or more companies within that TAM.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Access to capital through IPO
- Focus on high-growth biotech sector
Weaknesses
- No operating history
- Dependence on finding a suitable merger target
- SPAC structure inherently dilutive to shareholders
Opportunities
- Potential to acquire a promising biotech company
- Capitalize on favorable market conditions in the biotech sector
- Generate significant returns for investors
Threats
- Increased competition from other SPACs
- Regulatory changes impacting SPACs
- Unfavorable market conditions in the biotech sector
Competitors and Market Share
Key Competitors
Competitive Landscape
Competed with numerous other SPACs for suitable acquisition targets. Success depended on valuation, deal terms, and the attractiveness of the target company.
Growth Trajectory and Initiatives
Historical Growth: No historical growth prior to acquisition.
Future Projections: Future growth entirely dependent on the performance of the acquired company.
Recent Initiatives: Focus on identifying and completing a merger with a suitable biotech target.
Summary
Helix Acquisition Corp. II was a SPAC seeking a merger within the biotechnology sector. Its success hinged on finding a suitable acquisition target and navigating the competitive SPAC landscape. Its strengths included experienced management and access to capital, but it faced risks related to competition and market conditions. Prior to any acquisition, performance metrics are not indicative of an operating company's prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Financial News Sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The performance of SPACs is highly speculative and dependent on future events.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Helix Acquisition Corp. II Class A Ordinary Shares
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-02-09 | Chairperson & CEO Ms. Bihua Chen | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website |
Full time employees - | Website | ||
Helix Acquisition Corp. II focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.